KR102106485B1 - 폴리에틸렌글리콜이 수식된 인테그린 차단제 hm-3 및 그 응용 - Google Patents

폴리에틸렌글리콜이 수식된 인테그린 차단제 hm-3 및 그 응용 Download PDF

Info

Publication number
KR102106485B1
KR102106485B1 KR1020197020874A KR20197020874A KR102106485B1 KR 102106485 B1 KR102106485 B1 KR 102106485B1 KR 1020197020874 A KR1020197020874 A KR 1020197020874A KR 20197020874 A KR20197020874 A KR 20197020874A KR 102106485 B1 KR102106485 B1 KR 102106485B1
Authority
KR
South Korea
Prior art keywords
tumor
once
group
mpeg
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197020874A
Other languages
English (en)
Korean (ko)
Other versions
KR20190090872A (ko
Inventor
한메이 쉬
하이민 창
즈안 캉
Original Assignee
한메이 쉬
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한메이 쉬 filed Critical 한메이 쉬
Publication of KR20190090872A publication Critical patent/KR20190090872A/ko
Application granted granted Critical
Publication of KR102106485B1 publication Critical patent/KR102106485B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/04—Peptides being immobilised on, or in, an organic carrier entrapped within the carrier, e.g. gel, hollow fibre
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020197020874A 2011-11-21 2012-11-17 폴리에틸렌글리콜이 수식된 인테그린 차단제 hm-3 및 그 응용 Active KR102106485B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2011103705299A CN102417540A (zh) 2011-11-21 2011-11-21 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
CN201110370529.9 2011-11-21
PCT/CN2012/084788 WO2013075600A1 (zh) 2011-11-21 2012-11-17 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147016557A Division KR20140096373A (ko) 2011-11-21 2012-11-17 폴리에틸렌글리콜이 수식된 인테그린 차단제 hm-3 및 그 응용

Publications (2)

Publication Number Publication Date
KR20190090872A KR20190090872A (ko) 2019-08-02
KR102106485B1 true KR102106485B1 (ko) 2020-05-04

Family

ID=45942198

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197020874A Active KR102106485B1 (ko) 2011-11-21 2012-11-17 폴리에틸렌글리콜이 수식된 인테그린 차단제 hm-3 및 그 응용
KR1020147016557A Ceased KR20140096373A (ko) 2011-11-21 2012-11-17 폴리에틸렌글리콜이 수식된 인테그린 차단제 hm-3 및 그 응용

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147016557A Ceased KR20140096373A (ko) 2011-11-21 2012-11-17 폴리에틸렌글리콜이 수식된 인테그린 차단제 hm-3 및 그 응용

Country Status (7)

Country Link
US (2) US20140329759A1 (enExample)
EP (1) EP2784093B1 (enExample)
KR (2) KR102106485B1 (enExample)
CN (1) CN102417540A (enExample)
AU (1) AU2012343020B2 (enExample)
IN (1) IN2014CN04482A (enExample)
WO (1) WO2013075600A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102417540A (zh) * 2011-11-21 2012-04-18 中国药科大学 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
CN103656615B (zh) * 2013-12-11 2017-01-04 南京安吉生物科技有限公司 一种hm-3和铂类、紫杉醇类或他滨类药物在制备实体瘤药物中的用途
CN103623394A (zh) * 2013-12-11 2014-03-12 南京安吉生物科技有限公司 一种peg-hm-3和铂类、紫杉醇类或他滨类药物在制备实体瘤药物中的用途
CN103739671B (zh) * 2013-12-31 2015-08-26 郭向华 一种聚乙二醇修饰的抑制核因子-κB多肽及其应用
CN103739673B (zh) * 2013-12-31 2015-08-19 浙江元太生物科技有限公司 一种聚乙二醇修饰的抑制白介素-6多肽及其应用
CN103739669B (zh) * 2013-12-31 2015-08-26 浙江元太生物科技有限公司 一种抑制白介素-6多肽及其应用
CN103736078B (zh) * 2014-01-09 2017-12-12 南京安吉生物科技有限公司 mPEG‑HM‑3多肽冻干粉针制剂及其制备方法和用途
CN103720667B (zh) * 2014-01-09 2016-04-13 中国药科大学 Ap-25多肽冻干粉针制剂及其制备方法和用途
CN103819542A (zh) * 2014-02-28 2014-05-28 中国药科大学 一种聚乙二醇修饰及蛋白质融合表达的整合素阻断剂ap-25及其应用
CN104127378A (zh) * 2014-08-11 2014-11-05 中国药科大学 mPEG-SC20K-HM-3多肽注射液及其制备方法和用途
CN105622721A (zh) * 2015-12-16 2016-06-01 李斯文 一种聚乙二醇修饰的血管生成抑制剂hs-1及其应用
CN105646667A (zh) * 2016-04-06 2016-06-08 南京安吉生物科技有限公司 聚乙二醇修饰的血管生成抑制剂hm-1及其应用
CN108623693B (zh) * 2017-03-20 2022-03-25 徐寒梅 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用
CN109503700A (zh) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
CN107857800B (zh) * 2017-11-09 2020-05-05 北京赛升药业股份有限公司 一种长效整合素抑制剂及其应用
CN109879969B (zh) 2017-12-06 2024-04-09 天士力生物医药股份有限公司 一种hm-3融合蛋白及其应用
CN111855876B (zh) * 2020-07-10 2023-05-02 北京赛升药业股份有限公司 一种安替安吉肽有关物质的检测方法
CN113488512A (zh) * 2021-06-23 2021-10-08 深圳市华星光电半导体显示技术有限公司 显示面板及其制备方法
CN114230676B (zh) * 2021-12-22 2024-06-11 天士力生物医药股份有限公司 重组hm-3融合蛋白及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
MXPA05005469A (es) * 2002-11-25 2005-09-08 Attenuon Llc Peptidos que inhibien angiogenesis, migracion celular, invasion celular y proliferacion celular, composiciones y usos de los mismos.
CN1314705C (zh) * 2005-06-03 2007-05-09 中国药科大学 高效抑制血管生成多肽及其制备方法和应用
KR100863060B1 (ko) * 2006-06-02 2008-10-10 베이징 선바이오 바이오테크, 코오퍼레이션, 리미티드 암 억제 활동을 하는 재조합 단백질, 그 암호화 유전자 및 재조합 단백질을 활성성분으로 포함하는 암치료용 약학적 조성물
CN102145161A (zh) * 2011-04-07 2011-08-10 中国药科大学 整合素阻断剂在制备治疗肿瘤药物中的应用
CN102178656B (zh) * 2011-05-12 2012-08-22 内蒙古奇特生物高科技（集团）有限公司 Hm-3多肽冻干粉制剂及其制备方法
CN102205110B (zh) * 2011-05-18 2014-03-26 中国药科大学 整合素阻断剂在制备治疗新生血管性眼病药物中的应用
CN102417540A (zh) * 2011-11-21 2012-04-18 中国药科大学 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
CN104127378A (zh) * 2014-08-11 2014-11-05 中国药科大学 mPEG-SC20K-HM-3多肽注射液及其制备方法和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioconjugate Chem., Vol. 20, pp. 932-936 (2009.05.04.)*
Int. J. Mol. Sci., Vol. 12, pp. 2650-2663 (2011.04.19.)*

Also Published As

Publication number Publication date
KR20140096373A (ko) 2014-08-05
US20170100489A1 (en) 2017-04-13
EP2784093A1 (en) 2014-10-01
AU2012343020A1 (en) 2014-06-12
WO2013075600A1 (zh) 2013-05-30
KR20190090872A (ko) 2019-08-02
AU2012343020B2 (en) 2016-05-19
EP2784093B1 (en) 2019-10-09
IN2014CN04482A (enExample) 2015-09-04
US20140329759A1 (en) 2014-11-06
EP2784093A4 (en) 2015-08-05
CN102417540A (zh) 2012-04-18

Similar Documents

Publication Publication Date Title
KR102106485B1 (ko) 폴리에틸렌글리콜이 수식된 인테그린 차단제 hm-3 및 그 응용
EP2817329B1 (en) Polypeptides binding to human complement c5
US20240139279A1 (en) Cyclic prosaposin peptides and uses thereof
AU2015305299B2 (en) Disintegrin variants and pharmaceutical uses thereof
CN105315350A (zh) 抗肿瘤血管生成多肽mPEG-Mal-Cys-AS16
Chen et al. Unleashing the potential of natural biological peptide Macropin: Hydrocarbon stapling for effective breast cancer treatment
EP3854818A1 (en) Polypeptide capable of passing through blood-brain barrier
KR101323669B1 (ko) 암세포 특이적 세포괴사 유도 및 암 소멸 효과를 나타내는 세포사 유도 융합 펩타이드
WO2024223883A1 (en) Peptides for cancer therapy
HK40090948A (en) Cyclic prosaposin peptides and uses thereof
CN107857800B (zh) 一种长效整合素抑制剂及其应用
HK40013719A (en) Polypeptides binding to human complement c5
WO2020001495A1 (zh) 一类新的Bcl10聚合抑制剂及其应用
HK1233930A1 (en) Cyclic prosaposin peptides and uses thereof
HK1204790B (en) Polypeptides binding to human complement c5

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190717

Application number text: 1020147016557

Filing date: 20140617

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190717

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190906

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200317

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200424

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200424

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20230424

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240417

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20250415

Start annual number: 6

End annual number: 6